2013 Annual Meeting Archive Sunrise Seminars

Sunrise Seminars

2013 Annual Meeting Archive > 2013 Annual Meeting Sunrise Seminars

2013 Annual Meeting Sunrise Seminars

Sunrise Seminar I: TCGA Data Mining: Potential and Pitfalls
Sunrise Seminar II: Palliative Care in Gynecologic Cancer
Sunrise Seminar III: To Bleed or Not to Bleed, There is no Question
Sunrise Seminar IV: Breast Cancer
Sunrise Seminar V: It’s a Jungle Out There: The Importance of Patient Safety
Featured Poster Session I
Featured Poster Session II

Sunrise Seminar I

Sunrise Seminar I: TCGA Data Mining: Potential and Pitfalls
This session will review the nuts and bolts of TCGA comprehensive genomic profiling projects with a special emphasis on the recently completed ovarian and endometrial projects. Scientists, surgeons, or physicians who are interested in figuring out how to practically use the large volumes of data to enhance ongoing and planned research projects are encouraged to attend.
Moderator: Douglas Levine, MD, Memorial Sloan-Kettering Cancer Center
Faculty: Andrew Berchuck, MD, Duke University Medical Center

Sunrise Seminar II

Sunrise Seminar II: Palliative Care in Gynecologic Cancer
This session will discuss current topics in Palliative Care.
Moderator:
Cecelia Boardman, MD, HCA-Virginia Gynecologic Oncology
Moderator: Mary Gemignani, MD, MPH, Memorial Sloan-Kettering Cancer Center
Course Faculty:
Lois Ramondetta, MD, The University of Texas, MD Anderson Cancer Center and William Robinson III, MD, Tulane Medical School

Sunrise Seminar III

Sunrise Seminar III: To Bleed or Not to Bleed, There is no Question
This session will cover the management of placenta percretas/accretas and severe coagulopathic states/OB hemorrhage protocols. Case-based presentations will review coagulopathic patients and protocols/preparedness and intraoperative considerations.
Moderators: Paula Lee, MD, Duke University Medical Center and Jason Wright, Columbia University College of Physicians and Surgeons
Moderator: Mary Gemignani, MD, MPH, Memorial Sloan-Kettering Cancer Center
Course Faculty:
Linda Duska, MD, University of Virginia Health System and Mitchell Edelson, MD Hanjani Institute for Gynecologic Oncology

Sunrise Seminar IV

Sunrise Seminar IV: Breast Cancer
This session will include case presentations on breast cancer discussing bilateral mastectomy, prophylactic oophorectomy and fertility.
Moderator: Mary Gemignani, MD, MPH, Memorial Sloan-Kettering Cancer Center
Course Faculty: David Hetzel, MD, Hope Women’s Cancer Centers and Amer Karam, MD, UCLA School of Medicine

Sunrise Seminar V

Sunrise Seminar V: It’s a Jungle Out There: The Importance of Patient Safety
This session will discuss use of surgical checklists, practice examples and quality improvement projects.
Moderators: Charles Levenback, MD, The University of Texas, MD Anderson Cancer Center and Mitchell Edelson, MD, Hanjani Institute for Gynecologic Oncology
Course Faculty: Ana Tergas, MD, Johns Hopkins Medical Center

Featured Poster Session I

Featured Poster Session I, Abstracts 63-76

Moderator:
Laura Havrilesky, MD, Duke University Medical Center

Discussants:
Amanda Nickles Fader, MD, Greater Baltimore Medical Center/Johns Hopkins Medical Institutions
Robert Bristow, MD, UC Irvine Medical Center
Amer Karam, MD, UCLA School of Medicine
Laura Havrilesky, MD, Duke University Medical Center

Abstract 63

Receiver operating characteristic curve analysis to define the cut point for diagnosis of cervical intraepithelial neoplasia 3 or cancer by cervical cytology and Hhgh-risk Human Papillomavirus testing

R. Pretorius1, J. Belinson2, R. Burchette3, Y. Qiao4, R. Wu5

1Southern California Permanente Medical Group – Fontana, Fontana, CA, 2The Cleveland Clinic Foundation, Cleveland, OH, 3Southern California Permanente Medical Group, Los Robles, Pasadena, CA, 4The Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China, 5Peking University Shenzhen Hospital, Shenzhen, China

Abstract 64

Cervical cytology and HPV infection: A study of 15,565 women

E. Dickson, R. Vogel, L. Downs

University of Minnesota, Minneapolis, MN

Abstract 65

Male circumcision reduces high-risk Human Papillomavirus (HPV) viral shedding in female partners in Rakai, Uganda

M. Davis1, M. Grabowski2, P. Gravitt2, R. Gray2, G. Kigozi3, F. Nalugoda4, D. Serwadda3, A. Tobian5, S. Watya6, M. Wawer2

1Division of Gynecology Oncology University of California San Diego, La Jolla, CA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 3Rakai Health Sciences Program, Entebbe, Uganda, 4School of Public Health, Makerere University, Kampala, Uganda, 5Department of Pathology Johns Hopkins University Hospital, Baltimore, MD, 6Department of Urology, Makarere University, Kampala, Uganda

Abstract 66

Cost comparison of primary debulking surgery to neoadjuvant chemotherapy for treatment of advanced stage ovarian cancer in patients? 65 years old

M. Rowland1, C. Farris2, J. Lesnock3, T. Krivak4

1Magee Womens Hospital of UPMC, Pittsburgh, PA, 2Rand Corporation, Pittsburgh, PA, 3Mid-Atlantic Gynecologic Oncology of MonGeneral Hospital, Morgantown, WV, 4Magee-Womens Hospital of UPMC, Pittsburgh, PA

Abstract 67

Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model

C. Reade1, R. Osborne2, N. Shah3, L. Eiriksson1, J. Dodge4, F. Moens5, R. Goeree6

1Division of Gynecologic Oncology, University of Toronto, Toronto, Canada, 2Odette Cancer Center, Sunnybrook Health Sciences, Toronto, Canada, 3Brigham & Women’s Hospital, Boston, MA, 4Princess Margaret Hospital, Toronto, Canada, 5Juravinski Cancer Centre, Hamilton, Canada, 6PATH Research Institute, McMaster University, Hamilton, Canada

Abstract 68

A population-based study to evaluate SGO criteria for the identification of Lynch syndrome among endometrial cancer patients
A. Bruegl1, B. Djordjevic2, B. Fellman3, D. Urbauer3, R. Luthra3, K. Lu3, R. Broaddus3

1University of Texas M.D. Anderson Cancer Center, Houston, TX, 2University of Ottawa, Ottawa, ontario, Canada, 3The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract 69

Evaluation of the cost of CA 125 measurement, office visit and CT scan in the diagnosis of recurrent ovarian cancer

A. Armstrong1, R. DeBernardo2, J. Knight3, B. Otvos2

1University Hospitals Case Medical Center, Cleveland, OH, 2University McDonald Women’s Hospital, Cleveland, OH, 3The Cleveland Clinic Foundation, Cleveland, OH

Abstract 70

Addressing comfort-care in the ambulatory setting is associated with improved end-of-life quality measures among women with ovarian cancer

M. Lopez Acevedo, A. Abernethy, A. Kamal, G. Broadwater, A. Berchuck, P. Lee

Duke University Medical Center, Durham, NC

Abstract 71

Cost effectiveness of early palliative care intervention in recurrent platinum resistant ovarian cancer

W. Lowery1, A. Lowery1, J. Barnett2, M. Lopez Acecevdo1, P. Lee1, A. Alvarez-Secord1, L. Havrilesky1

1Duke University Medical Center, Durham, NC, 2Brooke Army Medical Center, Fort Sam Houston, TX

Abstract 72

Is a home-based palliative care treatment strategy preferable to standard chemotherapy in recurrent cervical cancer?

N. Phippen1, C. Leath2, C. Miller1, W. Lowery3, L. Havrilesky3, J. Barnett1

1Brooke Army Medical Center, Fort Sam Houston, TX, 2University of Alabama at Birmingham, Birmingham, AL, 3Duke University Medical Center, Durham, NC

Abstract 73

Symptoms of posttraumatic stress disorder in women who have undergone exenterative pelvic surgery for treatment of gynecologic malignancy

A. Bradford, P. Soliman, S. Westin, K. Lang, S. Anderson, L. Ramondetta

The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract 74

Changes in perceptions of screening over time among average-risk women undergoing ovarian cancer screening using the risk of ovarian cancer algorithm

L. Holman1, K. Lu1, M. Hernandez1, R. Bast1, S. Neal1, S. Skates2, D. Gershenson1, C. Sun1

1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Massachusetts General Hospital/Harvard University, Boston, MA

Abstract 75

Improved outcomes with beta blocker use in epithelial ovarian cancer patients

J. Watkins1, P. Thaker2, A. Nick1, L. Ramondetta1, S. Kumar3, K. Matsuo4, S. Lutgendorf5, P. Ramirez1, A. Sood1

1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Washington University, St. Louis, MO, 3Mayo Clinic, Rochester, MN, 4USC/LAC Medical Center Women and Children’s Hospital, Los Angeles, CA, 5University of Iowa Hospitals and Clinics, Iowa City, IA

Abstract 76

Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study

C. Craig1, S. Gibson2, C. Craig1, K. Osann3, J. Farley4, B. Monk4, D. Chase4

1St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 2University of Arizona, Tuscon, AZ, 3University of California Irvine – Medical Center, Orange, CA, 4Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, AZ

Featured Poster Session II

Featured Poster Session II, Abstracts 77-90

Moderator:
Pam Soliman, MD, The University of Texas, MD Anderson Cancer Center

Discussants:
John Farley, MD, COL, FACOG, FACS, St. Joseph’s Hospital and Medical Center
Edwin Alvarez, MD, University of California, San Diego School of Medicine
John Diaz, MD, University of Miami Sylvester Cancer Center

Abstract 77

Enrollment for cooperative group trials at a comprehensive cancer center
M. Leitao, M. Papaccioli, J. Mohr, C. Brown, R. Barakat, C. Aghajanian

Memorial Sloan-Kettering Cancer Center, New York, NY

Abstract 78

Phase 1A/B study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients with Solid, Endometrial, and Ovarian Cancers.

H. Chon1, A. Herschberger2, J. Lee2, R. Wenham2

1H.Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Abstract 79

The Lead-in Phase I/II Trial Design to Interrogate Novel Biological Agents

R. Coleman, W. Hu, M. Munsell, A. Sood

The University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract 80

Outcome Differences in Patients with Advanced Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers Treated With and Without Bevacizumab

L. Randall1, R. Burger2, H. Nguyen3, G. Kong3, M. Bookman4, G. Fleming5, B. Monk6, R. Mannel7, M. Birrer8

1UC Irvine Medical Center, Orange, CA, 2Fox Chase Cancer Center, Philadelphia, PA, 3Genentech, San Francisco, CA, 4University of Arizona, Tucson, AZ, 5University of Chicago, Chicago, IL, 6Creighton University School of Medicine, Phoenix, AZ, 7University of Oklahoma, Oklahoma City, OK, 8Massachusetts General Hospital/Harvard University, Boston, MA

Abstract 81

Characteristics and outcomes of gyn-oncology patients treated on phase I trials (1999-2012)

K. Slaughter1, B. James2, E. Nugent2, E. Bishop2, L. Perry2, D. McMeekin2, K. Moore2

1The University of Oklahoma, Oklahoma City, OK, 2University of Oklahoma, Oklahoma City, OK

Abstract 82

Homologous recombination defects are common in non-serous ovarian, fallopian tube, and peritoneal carcinomas.

K. Pennington, T. Walsh, M. Lee, C. Pennil, M. Harrell, K. Agnew, M. Rendi, R. Garcia, M. King, E. Swisher

University of Washington Medical Center, Seattle, WA

Abstract 83

Towards personalized PARP therapy: XRT-induced Rad51 predicts response to ABT-888 in ovarian cancer

M. Shah1, S. Nowsheen2, A. Katre1, Z. Dobbin1, B. Erickson1, R. Alvarez1, P. Konstantinopoulos3, E. Yang1, C. Landen1

1University of Alabama at Birmingham, Birmingham, AL, 2Mayo Clinic, Rochester, MN, 3Harvard Medical School, Boston, MA

Abstract 84

Etiologic Heterogeneity in Endometrial Cancer: Evidence from a Gynecologic Oncology Group Trial

L. Brinton1, A. Felix1, M. Sherman1, R. Zaino2, D. McMeekin3, W. Creasman4, D. Mutch5, D. Cohn6, J. Walker3, R. Moore7

1National Cancer Institute, Bethesda, MD, 2Penn State, Milton S. Hershey Medical Center, Hershey, PA, 3University of Oklahoma, Oklahoma City, OK, 4Medical University of South Carolina, Charleston, SC, 5Washington University School of Medicine, St. Louis, MO, 6Ohio State University, Columbus, OH, 7Women & Infants Hospital Brown University, Providence, RI

Abstract 85

Interleukin-Stimulated Cellular Therapy: Effectiveness Against Ovarian Cancer Using in vitro and in vivo Models

S. Ingersoll1, S. Ahmad1, H. Ahmed1, Y. Mohiuddin1, M. Srivastava1, J. Oyer1, R. Banks2, N. Finkler1, J. Edwards3, R. Holloway1

1Florida Hospital Cancer Institute, Orlando, FL, 2University of Central Florida, Orlando, FL, 3CTI Clinical Trial and Consulting Services, Cincinnati, OH

Abstract 86

Intraperitoneal Delivery of Human Natural Killer Cells for Treatment of Ovarian Cancer

M. Geller, D. Knorr1, L. Pribyl, L. Bendzick, V. mcCullar, J. Miller, D. Kaufman

University of Minnesota, Minneapolis, MN

Abstract 87

18F-fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Based Nomogram for Prediction of Incomplete Cytoreduction in Patients with Advanced Ovarian Cancer

S. Shim, D. Kim, P. Jung, S. Lee, J. Park, J. Lee, J. Kim, Y. Kim, Y. Kim, J. Nam

University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Abstract 88

Risk-Scoring System for the Individualized Prediction of Lymphatic Dissemination in Unstaged Patients with Endometrioid Endometrial Cancer

M. AlHilli, K. Podratz, S. Dowdy, J. Bakkum-Gamez, A. Weaver, M. McGree, G. Keeney, W. Cliby, A. Mariani

Mayo Clinic, Rochester, MN

Abstract 89

Predictors and incidence of radical vulvectomy complications in the modern era: a National Surgical Quality Improvement Program study

J. Lin1, M. Yu1, S. Beriwal1, T. Krivak1, G. Huang2, P. Sukumvanich1

1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Abstract 90

Laparoendoscopic Single Site Versus Conventional Laparoscopic Surgical Staging For Early-Stage Endometrial Cancer

J. Park, D. Kim, J. Kim, Y. Kim, Y. Kim, J. Nam

University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea